「しもそね整形外科・骨粗しょう症クリニック」は、患者様の治療を行うだけでなく、患者様に心のこもったおもてなしを提供することを大切な使命と考えています。
たとえ患者様が言葉に出さなくても、患者様が困っていること、求めていることを先読みして患者様を手助けいたします。
たとえ患者様が言葉に出さなくても、患者様が困っていること、求めていることを先読みして患者様を手助けいたします。
平成3年 九州大学医学部卒業 平成8年 九州大学大学院病理学教室卒業 国立福岡中央病院(現、九州医療センター)整形外科 九州大学医学部附属病院 整形外科 潤和会記念病院 整形外科 登別厚生年金病院 整形外科 新中間病院 整形外科 ドイツ マグデブルク大学病理学教室 九州労災病院 整形外科 |
日本整形外科学会専門医 日本整形外科学会認定リウマチ医 日本整形外科学会認定運動器リハビリテーション医 日本整形外科学会 日本骨粗鬆症学会 西日本整形外科・災害外科学会 日本関節鏡・膝・スポーツ整形外科学会 |
1. Naka T, Boltze C, Samii A, Samii M, Herold C, Ostertag H, Iwamoto Y, Oda Y, Tsuneyoshi M, Kuester D, Roessner A. Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma. Histopathology. 2009;54(5):607-13. 2. Naka T, Kuester D, Boltze C, Schulz TO, Samii A, Herold C, Ostertag H, Roessner A. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma. Hum Pathol. 2008;39(2):217-23. 3. Naka T, Kuester D, Boltze C, Scheil-Bertram S, Samii A, Herold C, Ostertag H, Krueger S, Roessner A. Expression of hepatocyte growth factor and c-MET in skull base chordoma. Cancer. 2008;112(1):104-10. 4. Naka T, Boltze C, Kuester D, Samii A, Herold C, Ostertag H, Iwamoto Y, Odae Y, Tsuneyoshi M, Roessner A. Histogenesis of intralesional fibrous septum in chordoma. Pathol Res Pract. 2005;201(6):443-7. 5. Naka T, Boltze C, Kuester D, Schulz TO, Schneider-Stock R, Kellner A, Samii A, Herold C, Ostertag H, Roessner A. Alterations of G1-S checkpoint in chordoma: the prognostic impact of p53 overexpression. Cancer. 2005;104(6):1255-63. 6. Naka T, Boltze C, Kuester D, Samii A, Herold C, Ostertag H, Iwamoto Y, Oda Y, Tsuneyoshi M, Roessner A. Intralesional fibrous septum in chordoma: a clinicopathologic and immunohistochemical study of 122 lesions. Am J Clin Pathol. 2005;124(2):288-94. 7. Naka T, Boltze C, Kuester D, Schulz TO, Samii A, Herold C, Ostertag H, Roessner A. Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B, and urokinase plasminogen activator in non-skull base chordoma. Am J Clin Pathol. 2004;122(6):926-30. 8. Naka T, Boltze C, Samii A, Herold C, Ostertag H, Iwamoto Y, Oda Y, Tsuneyoshi M, Kuester D, Roessner A. Skull base and nonskull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability. Cancer. 2003;98(9):1934-41. 9. Naka T, Oda Y, Iwamoto Y, Shinohara N, Chuman H, Fukui M, Tsuneyoshi M. Immunohistochemical analysis of E-cadherin, alpha-catenin, beta-catenin, gamma-catenin, and neural cell adhesion molecule (NCAM) in chordoma. J Clin Pathol. 2001;54(12):945-50. 10. Naka T, Iwamoto Y, Shinohara N, Ushijima M, Chuman H, Tsuneyoshi M. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors. Mod Pathol. 1997;10(8):832-8. 11. Naka T, Iwamoto Y, Shinohara N, Chuman H, Fukui M, Tsuneyoshi M. Cytokeratin subtyping in chordomas and the fetal notochord: an immunohistochemical analysis of aberrant expression. Mod Pathol. 1997;10(6):545-51. 12. Naka T, Fukuda T, Chuman H, Iwamoto Y, Sugioka Y, Fukui M, Tsuneyoshi M. Proliferative activities in conventional chordoma: a clinicopathologic, DNA flow cytometric, and immunohistochemical analysis of 17 specimens with special reference to anaplastic chordoma showing a diffuse proliferation and nuclear atypia. Hum Pathol. 1996;27(4):381-8. 13. Naka T, Fukuda T, Shinohara N, Iwamoto Y, Sugioka Y, Tsuneyoshi M. Osteosarcoma versus malignant fibrous histiocytoma of bone in patients older than 40 years. A clinicopathologic and immunohistochemical analysis with special reference to malignant fibrous histiocytoma-like osteosarcoma. Cancer. 1995;76(6):972-84. 14. Herold C, Giordano M, Naka T, Gerganov V, Samii M, Samii A. Clivus chordoma in continuity with a large pontine cyst. Skull Base. 2009;19(2):177-81. 15. Samii A, Gerganov VM, Herold C, Hayashi N, Naka T, Mirzayan MJ, Ostertag H, Samii M. Chordomas of the skull base: surgical management and outcome. J Neurosurg. 2007;107(2):319-24. 16. Miyanishi K, Kamo Y, Ihara H, Naka T, Hirakawa M, Sugioka Y. Risk factors for dysbaric osteonecrosis. Rheumatology (Oxford). 2006;45(7):855-8. 17. Oda Y, Naka T, Takeshita M, Iwamoto Y, Tsuneyoshi M. Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study. Hum Pathol. 2000;31(6):709-16. 18. Hirakawa N, Naka T, Yamamoto I, Fukuda T, Tsuneyoshi M. Overexpression of bcl-2 protein in synovial sarcoma: a comparative study of other soft tissue spindle cell sarcomas and an additional analysis by fluorescence in situ hybridization. Hum Pathol. 1996;27(10):1060-5. Tumors of the Central Nervous System, Volume 8: Astrocytoma, Medulloblastoma, Retinoblastoma, Chordoma, Craniopharyngioma, Oligodendroglioma, and Ependymoma (2012年 Springer刊行) 編集: Hayat, M.A. |